Background

What people are saying about CURE

Leading OTF Manufacturer CURE Pharmaceutical Comments on New Report Showing Exponential Growth in Thin Film Drug Manufacturing Market

OXNARD, Calif., June 07, 2017 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid… READ MORE

Cure Pharma’s API Delivery Tech on the Tip of the Tongue

In-Pharmatechnologist covered CURE’s newest patent filing and the potential of this new technology. Cure Pharmaceutical has submitted a patent application for… READ MORE

CURE Pharmaceutical and CannaKids Announce Research Collaboration with Technion-Israel Institute of Technology on Cancer-Fighting Cannabinoids

OXNARD, Calif., May 31, 2017 (GLOBE NEWSWIRE) — CURE Pharmaceutical  (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid… READ MORE

CURE Pharmaceutical Receives First Purchase Order Stemming from Product Development and License Agreement with Pharmaceutical Company, Meroven LTD

OXNARD, Calif., May 24, 2017 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development… READ MORE

Want to stay up to date with all CURE Pharmaceutical’s updates? Sign up with your email and we will send updates.